Method of detecting active tb
AssigneeNorwegian Institute of Public Health
InventorsOistein Ihle, Terje Einar Michaelsen, Carol Joanne Church Holm-Hansen
Life of this patent
Estimating the term…
Abstract
A method of detecting active TB in a patient comprising providing at least one peptide comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from SEQ. ID NOS. 1 to 8, or an antigenic fragment thereof and contacting the peptide with a biological sample obtained from the patient. The presence of an antibody in the sample binding to the peptide is indicative of active TB in the patient.
Claims27
1-18. (canceled)
A method of detecting active TB in a patient comprising the steps of:
- (a) providing at least one peptide comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from the group consisting of any one of SEQ. ID NOS. 1 to 3, 8, 4, 7, 6, 5 and an antigenic fragment of one of said sequences;
- (b) contacting the at least one peptide with a biological sample obtained from the patient;
- and
- (c) detecting the binding of the at least one peptide with an antibody in the biological sample wherein the presence of an antibody binding to the peptide is indicative of active TB in the patient.
A kit for the detection of active TB in a patient comprising at least two different peptides selected from the group consisting of the following (a) to (h):
- (a) a sequence with at least 80% sequence identity to SEQ. ID NO. 1 or an antigenic fragment thereof;
- (b) a sequence with at least 80% sequence identity to SEQ. ID NO. 2 or an antigenic fragment thereof;
- (c) a sequence with at least 80% sequence identity to SEQ. ID NO. 3 or an antigenic fragment thereof;
- (d) a sequence with at least 80% sequence identity to SEQ. ID NO. 8 or an antigenic fragment thereof;
- (e) a sequence with at least 80% sequence identity to SEQ. ID NO. 4 or an antigenic fragment thereof;
- (f) a sequence with at least 80% sequence identity to SEQ. ID NO. 7 or an antigenic fragment thereof;
- (g) a sequence with at least 80% sequence identity to SEQ. ID NO. 6 or an antigenic fragment thereof;
- and
- (h) a sequence with at least 80% sequence identity to SEQ. ID NO. 5 or an antigenic fragment thereof.
A kit for the detection of active TB in a patient comprising:
- (a) a solid phase;
- and
- (b) at least one peptide bound to the solid phase wherein the peptide comprises an amino acid sequence with at least 80% sequence identity to a sequence selected from the group consisting of any one of SEQ. ID NOS. 1 to 3, 8, 4, 7, 6, 5 and an antigenic fragment of one of said sequences.
A recombinant fusion protein comprising:
- (a) at least one antigenic region comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from the group consisting of any one of SEQ. ID NOS. 1 to 3, 8, 4, 7, 6, 5 and an antigenic fragment of one of said sequences;
- and
- (b) at least one anchoring region comprising a sequence of at least 25 amino acids.
An antigenic region comprising an amino acid sequence with at least 80% sequence identity to a sequence selected from the group consisting of any one of SEQ. ID NOS. 1 to 3, 8, 4, 7, 6, 5 and an antigenic fragment of one of said sequences, wherein the antigenic region is glycosylated.
Dependencies are inferred from the claim text.